Aquestive Therapeutics assured investors that its drug Anaphylm was on track for FDA approval by January 31, 2026, but the FDA identified significant deficiencies, delaying approval to at least Q1 2027. This caused the stock to plunge over 37% in one day, leading to a securities fraud lawsuit alleging the company misled investors about the drug's regulatory status. The lawsuit claims management knew of the issues but falsely maintained confidence, inflating the stock price. Investors have until May 4, 2026, to join the class action and seek recovery.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
